Passa al contenuto
Merck
Tutte le immagini(1)

Key Documents

View All Documentation

Y0001591

Flutamide for system suitability

European Pharmacopoeia (EP) Reference Standard

Sinonimo/i:

Flutamide, 2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C11H11F3N2O3
Numero CAS:
13311-84-7
Peso molecolare:
276.21
Numero MDL:
MFCD00072009
Codice UNSPSC:
41116107
ID PubChem:
329831499
NACRES:
NA.24

Grado

pharmaceutical primary standard

Famiglia di API

flutamide

Produttore/marchio commerciale

EDQM

applicazioni

pharmaceutical (small molecule)

Formato

neat

Temperatura di conservazione

2-8°C

Stringa SMILE

CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O

InChI

1S/C11H11F3N2O3/c1-6(2)10(17)15-7-3-4-9(16(18)19)8(5-7)11(12,13)14/h3-6H,1-2H3,(H,15,17)
MKXKFYHWDHIYRV-UHFFFAOYSA-N

Informazioni sul gene

human ... AR(367)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Descrizione generale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Applicazioni

Flutamide for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Confezionamento

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Altre note

Sales restrictions may apply.

Avvertenze

Warning

Indicazioni di pericolo

H302,H351,H361,H373,H411

Classi di pericolo

Acute Tox. 4 Oral - Aquatic Chronic 2 - Carc. 2 - Repr. 2 - STOT RE 2

Organi bersaglio

Liver

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

Ci dispiace, ma al momento non ci sono COA disponibili online per questo prodotto.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Javier Brahm et al.
Annals of hepatology, 10(1), 93-98 (2011-02-09)
Flutamide is a non-steroidal anti-androgenic drug, commonly used in the treatment of advanced prostate cancer, acne and hirsutism. This drug may induce various degrees of liver injury, including acute liver failure (ALF), with further need for liver transplantation. Here, we
Pengliang Shen et al.
The Prostate, 74(9), 946-958 (2014-04-17)
Kruppel-like factors (KLFs) are involved in various biological processes; emerging studies have indicated that KLF9 plays a critical role in regulating tumorigenesis. The role of KLF9 in prostate cancer (PCa), however, has not yet been investigated. The expression of KLF
B R Goldspiel et al.
DICP : the annals of pharmacotherapy, 24(6), 616-623 (1990-06-01)
Flutamide is a nonsteroidal pure antiandrogen that acts by inhibiting the uptake and/or binding of dihydrotestosterone to the target cell receptor, thus interfering with androgen action. Flutamide is well absorbed orally and extensively metabolized; its active metabolite, 2-hydroxyflutamide, is formed
Lourdes Ibáñez et al.
Human reproduction update, 12(3), 243-252 (2006-01-13)
Polycystic ovary syndrome (PCOS) is a variable disorder that is characterized in adolescents and young women by a broad spectrum of anomalies, including hyperandrogenemia, insulin resistance, dyslipidemia, body adiposity and low-grade inflammation. At present, there is no approved therapy for
F Labrie et al.
Journal of steroid biochemistry, 33(4B), 817-821 (1989-10-01)
In order to achieve a more complete blockade of androgens of both testicular and adrenal origins, 223 patients with advanced prostate cancer (stage D2 with bone metastases) received the combination therapy with the antiandrogen Flutamide and the LH-RH agonist [D-Trp6,des-Gly-HN10(2)]
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.